Description

Apollo’s McKesson Takeover Bet Signals A Bigger Strategy Unfolding!

McKesson has entered a new phase in its portfolio reshaping after Apollo affiliates agreed to invest $1.25 billion in convertible preferred equity for roughly a 13% stake in the company’s medical-surgical solutions business, implying an enterprise valuation of about $13 billion for that segment. The transaction arrives as McKesson continues preparing the unit for separation, with management targeting an IPO in the second half of calendar 2027, subject to market conditions and approvals. The timing matters because it follows a period in which McKesson has been directing capital and management attention toward faster-growing, higher-margin areas such as oncology, multispecialty care, and biopharma services, while keeping the medical-surgical business operationally stable but strategically non-core.